The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 28, 2021
Filed:
Dec. 18, 2019
Florida State University Research Foundation, Inc., Tallahassee, FL (US);
The Johns Hopkins University, Baltimore, MD (US);
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Hengli Tang, Tallahassee, FL (US);
Emily M. Lee, Tallahassee, FL (US);
Anil Mathew Tharappel, Tallahassee, FL (US);
Hongjun Song, Baltimore, MD (US);
Guo-Li Ming, Baltimore, MD (US);
Wei Zheng, Rockville, MD (US);
Miao Xu, Rockville, MD (US);
Shu Yang, Rockville, MD (US);
Ruili Huang, Rockville, MD (US);
Wenwei Huang, Rockville, MD (US);
Khalida Shamim, Gaithersburg, MD (US);
Hao Li, Rockville, MD (US);
Florida State University Research Foundation, Inc., Tallahassee, FL (US);
The Johns Hopkins University, Baltimore, MD (US);
The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Abstract
The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as dengue virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as dengue virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such dengue virus infections.